

Kenneth K Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11769923/publications.pdf>

Version: 2024-02-01

118
papers

8,579
citations

61984

43
h-index

43889

91
g-index

118
all docs

118
docs citations

118
times ranked

10520
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. <i>AAPS Journal</i> , 2016, 18, 737-745.	4.4	11
2	A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase, in acute leukemias: a California Cancer Consortium study. <i>Leukemia and Lymphoma</i> , 2016, 57, 2307-2314.	1.3	6
3	Differential association for <i>N</i> -acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population. <i>Oncotarget</i> , 2016, 7, 40012-40024.	1.8	7
4	CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia. <i>Molecular Pharmaceutics</i> , 2015, 12, 2010-2018.	4.6	23
5	Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1332-1336.	1.3	6
6	In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia. <i>AAPS Journal</i> , 2013, 15, 242-249.	4.4	16
7	Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 2355-2367.	7.0	170
8	Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 136-147.	1.4	63
9	Curcumin Down-Regulates DNA Methyltransferase 1 and Plays an Anti-Leukemic Role in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2013, 8, e55934.	2.5	121
10	A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2'-O-Methylphosphorothioate Mir-29b. <i>Blood</i> , 2013, 122, 3933-3933.	1.4	0
11	Reactivation of RASSF1A in Breast Cancer Cells by Curcumin. <i>Nutrition and Cancer</i> , 2012, 64, 1228-1235.	2.0	80
12	Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. <i>Blood</i> , 2012, 119, 1240-1247.	1.4	90
13	Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation. <i>Cancer Cell</i> , 2012, 22, 645-655.	16.8	150
14	Determination of cellular uptake and intracellular levels of Cenersen (Aezea [®] , EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 71, 228-232.	2.8	8
15	RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 5229-5238.	1.4	115
16	Synthetic MicroRNA Cassette Dosing: Pharmacokinetics, Tissue Distribution and Bioactivity. <i>Molecular Pharmaceutics</i> , 2012, 9, 1638-1644.	4.6	24
17	A liquid chromatography-tandem mass spectrometric method for quantification of curcumin-O-glucuronide and curcumin in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 900, 89-93.	2.3	19
18	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 6025-6031.	1.4	127

#	ARTICLE	IF	CITATIONS
19	Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study. <i>International Journal of Cancer</i> , 2012, 130, 1174-1183.	5.1	16
20	Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 679-689.	2.3	147
21	Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 2422-2422.	1.4	1
22	Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 3578-3578.	1.4	0
23	Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Blood</i> , 2012, 120, 3616-3616.	1.4	0
24	Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells. <i>AAPS Journal</i> , 2011, 13, 131-140.	4.4	5
25	Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells. <i>AAPS Journal</i> , 2011, 13, 357-64.	4.4	63
26	Effects of Human Oral Mucosal Tissue, Saliva, and Oral Microflora on Intraoral Metabolism and Bioactivation of Black Raspberry Anthocyanins. <i>Cancer Prevention Research</i> , 2011, 4, 1209-1221.	1.5	93
27	Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 81-81.	1.4	0
28	Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes. <i>Blood</i> , 2011, 118, 1434-1434.	1.4	0
29	A Novel Ultrasensitive Hybridization-Based ELISA Method for 2-Methoxyphosphorothiolate MicroRNAs and Its In vitro and In vivo Application. <i>AAPS Journal</i> , 2010, 12, 556-568.	4.4	19
30	A liquid chromatography-tandem mass spectrometric method for quantification of curcuminoids in cell medium and mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3045-3051.	2.3	48
31	Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing. <i>Journal of Controlled Release</i> , 2010, 141, 62-69.	9.9	80
32	Sp1/NF κ B/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia. <i>Cancer Cell</i> , 2010, 17, 333-347.	16.8	235
33	Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. <i>British Journal of Haematology</i> , 2010, 150, 189-195.	2.5	59
34	Environmental Tobacco Smoke in Relation to Bladder Cancer Risk-The Shanghai Bladder Cancer Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3087-3095.	2.5	33
35	Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 7473-7478.	7.1	443
36	Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide-Based Therapeutic Strategy in Acute Myeloid Leukemia. <i>Molecular Pharmaceutics</i> , 2010, 7, 196-206.	4.6	38

#	ARTICLE	IF	CITATIONS
37	The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 150-150.	1.4	4
38	Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2010, 116, 1475-1475.	1.4	3
39	Tetrahydrouridine Co-Administration Improves Oral Bioavailability and Dampens Inter-Individual Variability of Decitabine Pharmacokinetics In Baboons. <i>Blood</i> , 2010, 116, 2081-2081.	1.4	0
40	Modulation of DNA Methylation by a Sesquiterpene Lactone Parthenolide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 505-514.	2.5	133
41	Distribution of Anthocyanins Delivered from a Bioadhesive Black Raspberry Gel Following Topical Intraoral Application in Normal Healthy Volunteers. <i>Pharmaceutical Research</i> , 2009, 26, 977-986.	3.5	38
42	A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels. <i>Pharmaceutical Research</i> , 2009, 26, 1504-1515.	3.5	61
43	A rapid and sensitive LC-MS/MS method for quantification of four anthocyanins and its application in a clinical pharmacology study of a bioadhesive black raspberry gel. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 4027-4034.	2.3	29
44	Curcumin is a potent DNA hypomethylation agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 706-709.	2.2	284
45	Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry. <i>Analytical Biochemistry</i> , 2009, 391, 106-113.	2.4	25
46	Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense Oligodeoxyribonucleotide against Bcl-2. <i>Molecular Pharmaceutics</i> , 2009, 6, 221-230.	4.6	86
47	Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.. <i>Blood</i> , 2009, 114, 3782-3782.	1.4	0
48	Evidence of MicroRNA-29b and Sp1/NF- κ B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.. <i>Blood</i> , 2009, 114, 938-938.	1.4	1
49	Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2227-2233.	3.3	7
50	A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 3434-3440.	7.0	8
51	Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. <i>Carcinogenesis</i> , 2008, 29, 1386-1393.	2.8	52
52	Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF- κ B-dependent DNA methyltransferase activity in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 2364-2373.	1.4	132
53	Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2007, 25, 3884-3891.	1.6	324
54	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 15805-15810.	7.1	1,538

#	ARTICLE	IF	CITATIONS
55	Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 953-960.	2.5	77
56	Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. <i>Nucleic Acids Research</i> , 2007, 35, e31-e31.	14.5	71
57	Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry. <i>AAPS Journal</i> , 2006, 8, E743-E755.	4.4	28
58	Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 1117-1126.	1.5	73
59	A Specific Picomolar Hybridization-Based ELISA Assay for the Determination of Phosphorothioate Oligonucleotides in Plasma and Cellular Matrices. <i>Pharmaceutical Research</i> , 2006, 23, 1251-1264.	3.5	54
60	Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 532-539.	2.3	8
61	The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide. <i>Clinical Cancer Research</i> , 2006, 12, 2902-2911.	7.0	42
62	A phase II study of chloroquinoline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). <i>Investigational New Drugs</i> , 2006, 24, 343.	2.6	0
63	Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 825, 201-213.	2.3	71
64	Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 389-399.	1.6	26
65	Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 2998-3008.	7.0	44
66	Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentais mediated by Reversible MDR1 Induction in Human Cancer Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 467-475.	2.5	63
67	Efflux of Depsipeptide FK228 (FR901228, NSC-630176) Is Mediated by P-Glycoprotein and Multidrug Resistance-Associated Protein 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 268-276.	2.5	69
68	Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. <i>Journal of Clinical Oncology</i> , 2005, 23, 3404-3411.	1.6	143
69	Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.. <i>Blood</i> , 2005, 106, 1861-1861.	1.4	6
70	Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus-Positive Lymphoproliferative Disorder. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1447-1457.	6.3	29
71	Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 85-88.	2.3	30
72	Carotenoids/vitamin C and smoking-related bladder cancer. <i>International Journal of Cancer</i> , 2004, 110, 417-423.	5.1	74

#	ARTICLE	IF	CITATIONS
73	Recent Developments in the Maytansinoid Antitumor Agents. ChemInform, 2004, 35, no.	0.0	1
74	An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2004, 36, 815-821.	2.8	6
75	A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 2004, 105, 959-967.	1.4	371
76	Recent Developments in the Maytansinoid Antitumor Agents. Chemical and Pharmaceutical Bulletin, 2004, 52, 1-26.	1.3	310
77	Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Communications in Mass Spectrometry, 2003, 17, 757-766.	1.5	32
78	Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis, 2003, 24, 483-489.	2.8	111
79	DNA Sequence Specificity for Topoisomerase II Poisoning by the Quinoxaline Anticancer Drugs XK469 and CQS. Molecular Pharmacology, 2003, 63, 1382-1388.	2.3	39
80	Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 2003, 101, 425-432.	1.4	221
81	Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemotherapy and Pharmacology, 2002, 49, 367-374.	2.3	28
82	Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. Cancer Chemotherapy and Pharmacology, 2002, 50, 445-453.	2.3	14
83	Electrospray LC-MS/MS quantitation, stability, and preliminary pharmacokinetics of bradykinin antagonist polypeptide B201 (NSC 710295) in the mouse. Journal of Pharmaceutical and Biomedical Analysis, 2002, 28, 601-612.	2.8	22
84	Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clinical Cancer Research, 2002, 8, 718-28.	7.0	410
85	Cytotoxic Mechanism of XK469: Resistance of Topoisomerase II ² Knockout Cells and Inhibition of Topoisomerase I. Biochemical and Biophysical Research Communications, 2001, 280, 1155-1160.	2.1	22
86	Permanent hair dyes and bladder cancer risk. International Journal of Cancer, 2001, 94, 905-906.	5.1	23
87	Quantitation of monoterpenoid compounds with potential medicinal use in biological fluids. Journal of Chromatography A, 2001, 936, 47-57.	3.7	14
88	Topoisomerase II Poisoning by ICRF-193. Journal of Biological Chemistry, 2001, 276, 44488-44494.	3.4	77
89	A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2000, 22, 33-44.	2.8	29
90	Stereoselective pharmacokinetics of ifosfamide in male and female rats. AAPS PharmSci, 2000, 2, 98-108.	1.3	4

#	ARTICLE	IF	CITATIONS
91	Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma. Biomedical Applications, 1999, 728, 85-95.	1.7	29
92	NB1-C16-insulin: site-specific synthesis, purification, and biological activity. Pharmaceutical Research, 1999, 16, 1680-1686.	3.5	9
93	Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs. Cancer Chemotherapy and Pharmacology, 1999, 43, 59-67.	2.3	23
94	Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. Cancer Chemotherapy and Pharmacology, 1999, 44, 124-130.	2.3	22
95	Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Research and Treatment, 1998, 51, 29-38.	2.5	62
96	Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. Investigational New Drugs, 1997, 15, 195-206.	2.6	41
97	Synthesis of deuterium labeled perillyl alcohol and dual C-13 and deuterium labeled perillic acid, major metabolites of d-limonene. Journal of Labelled Compounds and Radiopharmaceuticals, 1997, 39, 369-377.	1.0	5
98	Stereospecific synthesis of tetradeuterated (R)- and (S)-ifosfamide. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 105-115.	1.0	6
99	Gas chromatographic-mass spectrometric assay for N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in rat plasma. Biomedical Applications, 1996, 678, 219-225.	1.7	12
100	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer, 1995, 75, 2782-2782.	4.1	1
101	Preclinical pharmacokinetics and stability of isophosphoramidate mustard. Cancer Chemotherapy and Pharmacology, 1994, 33, 391-398.	2.3	29
102	Preclinical pharmacokinetics and stability of isophosphoramidate mustard. Cancer Chemotherapy and Pharmacology, 1994, 33, 391-398.	2.3	2
103	Analysis of 4-hydroxycyclophosphamide by gas chromatography-mass spectrometry in plasma. Biomedical Applications, 1989, 495, 131-138.	1.7	17
104	Analysis of clomesone in plasma by gas chromatography-electrolytic conductivity detection. Biomedical Applications, 1988, 428, 331-339.	1.7	1
105	Identification and quantitation of alcohosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry. Biomedical & Environmental Mass Spectrometry, 1987, 14, 167-172.	1.6	9
106	Identification of new metabolites of phosphoramidate and non-nitrogen mustards and cyclophosphamide in rat urine using ion cluster techniques. Biological Mass Spectrometry, 1986, 13, 145-154.	0.5	7
107	Inhibition of proliferation without affecting the generation of cytotoxicity in the human mixed lymphocyte reaction. Cellular Immunology, 1985, 90, 281-294.	3.0	3
108	Kinetics of Phosphoramidate Mustard Hydrolysis in Aqueous Solution. Journal of Pharmaceutical Sciences, 1985, 74, 1283-1292.	3.3	33

#	ARTICLE	IF	CITATIONS
109	Proton magnetic resonance studies of the decomposition of 4-hydroxycyclophosphamide, a microsomal metabolite of cyclophosphamide. <i>Pharmaceutical Research</i> , 1984, 01, 89-92.	3.5	3
110	Synthesis of singly 2H-, 3H-, and 14C- and doubly labeled acetaminophen, phenacetin, and p-acetanisidine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1982, 19, 321-329.	1.0	5
111	Tissue disposition of doxorubicin in experimental animals. <i>Medical and Pediatric Oncology</i> , 1982, 10, 259-267.	1.0	20
112	Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: Clinical and pharmacokinetic aspects. <i>Cancer</i> , 1981, 48, 1088-1095.	4.1	36
113	Distribution of adriamycin in cancer patients. Tissue uptakes, plasma concentration after IV and hepatic IA administration. <i>Cancer</i> , 1980, 45, 2231-2239.	4.1	89
114	5-Azacytidine Hydrolysis Kinetics Measured by High-Pressure Liquid Chromatography and 13C-NMR Spectroscopy. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 807-812.	3.3	44
115	Synthesis of 5-azacytidine-6-13C and -6-14C. <i>Journal of Medicinal Chemistry</i> , 1977, 20, 598-600.	6.4	10
116	Carbon-13 nuclear magnetic resonance studies of coumarin and related compounds. <i>Tetrahedron</i> , 1977, 33, 899-906.	1.9	41
117	Warfarin STEREOCHEMICAL ASPECTS OF ITS METABOLISM AND THE INTERACTION WITH PHENYLBUTAZONE. <i>Journal of Clinical Investigation</i> , 1974, 53, 1607-1617.	8.2	267
118	Absolute configurations of the four warfarin alcohols. <i>Journal of Medicinal Chemistry</i> , 1972, 15, 1265-1270.	6.4	70